Evidence map›Paper›PMID 32407682›Full record

ReviewTrends in parasitology2020

Plasmodium vivax in the Era of the Shrinking P. falciparum Map.

Ric N Price, Robert J Commons, Katherine E Battle, Kamala Thriemer, Kamini Mendis

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in parasitology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 7 pooled it
26.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

168 citing papers in PubMed, 7 syntheses or guidelines pooled it, 277 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Population heterogeneity in Plasmodium vivax relapse risk.PLoS neglected tropical diseases · 2022
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Effect of higher dose primaquine for the radical cure ofThe Lancet regional health. Western Pacific · 2026
    Article
  18. Article
  19. Article
  20. Article

108 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 5 countries.

Ric N PriceGlobal Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Electronic address: rprice@menzies.edu.au.
Robert J CommonsGlobal Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia; Internal Medicine Services, Ballarat Health Services, Ballarat, Victoria, Australia.
Katherine E BattleInstitute for Disease Modeling, Bellevue, WA, USA.
Kamala ThriemerGlobal Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
Kamini MendisFaculty of Medicine, University of Colombo, Kynsey Road, Sri Lanka.
Charles Darwin University · AUBellevue Hospital Center · USMahidol University · THUniversity of Colombo · LK

Funding

Wellcome Trust 200909Wellcome Trust 200909/Z/16/Z
6 · The paper itself

Abstract

Plasmodium vivax is an important cause of malaria, associated with a significant public health burden. Whilst enhanced malaria-control activities have successfully reduced the incidence of Plasmodium falciparum malaria in many areas, there has been a consistent increase in the proportion of malaria due to P. vivax in regions where both parasites coexist. This article reviews the epidemiology and biology of P. vivax, how the parasite differs from P. falciparum, and the key features that render it more difficult to control and eliminate. Since transmission of the parasite is driven largely by relapses from dormant liver stages, its timely elimination will require widespread access to safe and effective radical cure.

Indexed as

AnimalsAntimalarialsDisease EradicationHumansIncidenceMalaria, FalciparumMalaria, VivaxPlasmodium falciparumPlasmodium vivaxAntimalarialsepidemiologyPlasmodium falciparumPlasmodium vivaxprimaquine

Identifiers

PMID32407682
PMCPMC7297627
OpenAlexW3018160686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.